ClinicalTrials.gg

Program

Vorinostat

Also written as “vorinostat”, “Vorinostat (SAHA)” and “MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months”.

Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma · Neoplasms · Rett Syndrome, led by 3 companies.

Furthest: phase 3, since Aug 5, 200529 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck260 open or runningphase 3since Aug 5, 2005Sep 10, 2004none ahead
Unravel Biosciences22 open or runningphase 1since Aug 14, 2025Aug 14, 2025Dec 31, 2026phase 1 · NCT07150013
Jubilant DraxImage10 open or runningphase 2since Jun 7, 2018Jun 7, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Sep 10, 2004.

  1. May 14, 2007Phase 3 study in Stage IIIB or IV Non-Small Cell Lung CancerMerck · NCT00473889 · 253 enrolled
  2. May 24, 2007Phase 1 study in LeukemiaMerck · NCT00479232 · 71 enrolled
  3. Jun 14, 2007Phase 2 study in Myelodysplastic SyndromesMerck · NCT00486720 · 22 enrolled
  4. Feb 29, 2008Phase 1 study in Advanced Cancer RelapsedMerck · NCT00632931 · 25 enrolled
  5. Mar 17, 2008Phase 1 study in RecurrenceMerck · NCT00642954 · 31 enrolled
  6. Sep 8, 2008Phase 1 study in NeoplasmsMerck · NCT00750178 · 30 enrolled
  7. Oct 9, 2008Phase 1 study in LymphomaMerck · NCT00771472 · 10 enrolled
  8. Oct 14, 2008Phase 2 study in RecurrenceMerck · NCT00773838 · 143 enrolled
  9. Oct 14, 2008Phase 3 study in Multiple MyelomaMerck · NCT00773747 · 637 enrolled
  10. Mar 4, 2009Phase 1 study in Multiple MyelomaMerck · NCT00858234 · 9 enrolled
  11. Apr 2, 2009Phase 2 study in LymphomaMerck · NCT00875056 · 56 enrolled
  12. May 21, 2009Phase 2 study in Advanced CancerMerck · NCT00907738 · 27 enrolled
  13. Jun 7, 2018Jubilant DraxImage's first study: phase 2 study in NeuroblastomaNew to Jubilant DraxImageJubilant DraxImage · NCT03561259 · 60 enrolled · United States
  14. Aug 14, 2025Unravel Biosciences's first studies: 2 phase 1 studiesNew to Unravel BiosciencesUnravel Biosciences · NCT07150026, NCT07150013

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Pitt-Hopkins syndromeUnravel Biosciences · NCT07150026
  2. Dec 31, 2026Primary completion: phase 1 study in Rett SyndromeUnravel Biosciences · NCT07150013

TargetBeta

“Histone deacetylase 1 inhibitor; Histone deacetylase 3 inhibitor; Histone deacetylase 6 inhibitor; Histone deacetylase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
givinostatruleItalfarmacophase 323
givinostat hydrochlorideruleItalfarmacophase 21

Studies

All 29 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07150026Pitt-Hopkins syndrome · Colombia1RecruitingUnravel BiosciencesDec 31, 20265
NCT07150013Rett Syndrome · Colombia1RecruitingUnravel BiosciencesDec 31, 202615
NCT03561259Neuroblastoma · United States2UNKNOWNJubilant DraxImageDec 1, 202360
NCT00907738Advanced Cancer2CompletedMerckJun 201027
NCT00875056Lymphoma2CompletedMerckSep 6, 201156
NCT00858234Multiple Myeloma1CompletedMerckJun 11, 20109
NCT00773838Recurrence2CompletedMerckMay 16, 2011143
NCT00773747Multiple Myeloma3CompletedMerckSep 8, 2011637
NCT00771472Lymphoma1CompletedMerckJul 201110
NCT00750178Neoplasms1CompletedMerckAug 1, 200530
NCT00642954Recurrence1CompletedMerckSep 3, 201231
NCT00632931Advanced Cancer Relapsed1CompletedMerckMay 200825
NCT00486720Myelodysplastic Syndromes2TerminatedMerckJul 200922
NCT00479232Leukemia1CompletedMerckApr 201071
NCT00473889Stage IIIB or IV Non-Small Cell Lung Cancer3TerminatedMerckDec 2008253
NCT00424775Neoplasms1TerminatedMerckMar 20073
NCT00423449Carcinoma, Non-Small-Cell Lung1CompletedMerckApr 201061
NCT00373490Neoplasms1CompletedMerckOct 200716
NCT00251589Carcinoma, Non-Small-Cell Lung2TerminatedMerckOct 200723
NCT00128102Mesothelioma3CompletedMerckJul 15, 2011661
NCT00127140Lymphoma1CompletedMerckApr 201210
NCT00127127Neoplasms1CompletedMerckAug 21, 200918
NCT00127101Lymphoma1TerminatedMerckOct 200823
NCT00126451Breast Neoplasms2TerminatedMerckOct 11, 200516
NCT00111813Multiple Myeloma1CompletedMerckDec 200934
NCT00109109Multiple Myeloma1TerminatedMerckFeb 14, 200660
NCT00106626Carcinoma, Non-Small-Cell Lung1CompletedMerckDec 200752
NCT00097929Lymphoma, B-Cell2CompletedMerckJul 31, 200618
NCT00091559Lymphoma, T-Cell, Cutaneous2CompletedMerckNov 23, 200574

How it is read

Names in the registry

  • “Vorinostat”, 12 entries
  • “vorinostat”, 12 entries
  • “Vorinostat (SAHA)”, 2 entries
  • “MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months”, 2 entries
  • “131-MIBG + Vorinostat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.